Glucose oxidase, arylacetonitrilase, and guanylate cyclase

This target entry refers to a specific triad of enzymes—glucose oxidase (EC 1.1.3.4), arylacetonitrilase (EC 3.5.5.5), and guanylate cyclase (EC 4.6.1.2)—that are frequently listed together in pharmacological databases as targets or predicted activities for the drug hydralazine (Systematic Reviews in Pharmacy, 2022) [12]. Guanylate cyclase is a key human enzyme that produces cGMP, a second messenger that triggers smooth muscle relaxation and is the primary mediator of hydralazine's antihypertensive effects (PubChem) [12]. In contrast, glucose oxidase and arylacetonitrilase are non-human enzymes, found in fungi and bacteria respectively, whose inclusion in this profile often stems from computational activity predictions like PASS or historical database annotations in DrugBank (BRENDA; KEGG) [3, 6, 13]. The stimulation of guanylate cyclase is a well-validated mechanism for}

Other names

Hydralazine target profileGOX/NIT/GCPredicted hydralazine targets

Hydralazine acts as a direct-acting vasodilator by stimulating guanylate cyclase, which increases intracellular cGMP levels and leads to the relaxation of arterial smooth muscle (Systematic Reviews in Pharmacy, 2022) [12]. It is also reported to have inhibitory effects on glucose oxidase and arylacetonitrilase, though these are primarily based on predictive modeling and non-human enzyme assays (DrugBank; PASS) [12, 13].